Our CST scientists work at the bench daily to produce and validate your antibodies. They have hands-on knowledge of each antibody's performance. These same scientists provide technical support and assistance.
Cell Signaling Technology Announces the Release of a First to Market IHC-Approved VISTA Antibody
New York – September 16, 2015 – Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of a first to market, IHC-approved, human-specific, VISTA rabbit monoclonal antibody (mAb), for use in biomedical research. This announcement was made at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, September 16-19, 2015 in New York, NY.
VISTA (V-Domain Ig Suppressor of T Cell Activation, C10orf54, GI24, SISP1) is a negative checkpoint control protein that regulates T cell activation and immune response. Its role in negative checkpoint control has made it an important target in the field of tumor immunology; a field that seeks to develop better therapeutic options by dismantling the mechanisms tumors use to generate and thrive in their own immunosuppressive microenvironments.
VISTA (D1L2G™) XP® Rabbit mAb #64953 is validated, using CST’s rigorous standards, to recognize human VISTA in immunohistochemistry and western blot research applications.
Today’s announcement follows the release of a suite of antibodies designed to recognize pivotal targets within the field of tumor immunology research. These include PD-L1 (E1L3N®) XP® Rabbit mAb #13684, PD-1 (D3W4U) Rabbit mAb #15121, CTLA-4 (D4E9I) Rabbit mAb #15119, OX40 (D1S6L) Rabbit mAb #15123, B7-H3 (D9M2L) XP® Rabbit mAb #14058, and B7-H4 (D1M8I) XP® Rabbit mAb #14572.
“We feel the release of these products strengthens our position as a leading supplier of complete turnkey solutions to the tumor immunology community. We recognize that the study of tumor immunology has the potential to improve both our understanding of how cancer progresses and our approach to treating it, as such we are pleased to offer products that help advance this important field of study,” said Michael J. Comb, CEO of CST.
CST Principal Scientist, Matt Silver, Ph.D. will present a poster demonstrating the performance of these antibodies at the meeting, on Wednesday, September 16, 2015.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
XP®, D1L2G™, E1L3N®, Cell Signaling Technology®, and CST™ are trademarks of Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc.
Rebecca J. Reppucci, MBA, 978-867-2382
Director of Marketing Communications